PCRX Q3 2020 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M+12.2% YoY

Gross Profit

$87M74.5% margin

Operating Income

$18M15.0% margin

Net Income

$130M110.8% margin

EPS (Diluted)

$2.94

QoQ Revenue Growth

+55.6%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$32M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$636M

Stockholders' Equity

$585M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$105M	+12.2%
Gross Profit	$87M	$82M	+6.2%
Operating Income	$18M	$2M	+630.2%
Net Income	$130M	-$6M	+2237.7%

Revenue Segments

Product

$117M99%

Royalty

$595,0001%